

A-Engrossed
Senate Bill 450

Ordered by the House May 16
Including House Amendments dated May 16

Sponsored by Senator BONHAM (Pre-session filed.)

SUMMARY

The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject to consideration by the Legislative Assembly. It is an editor's brief statement of the essential features of the measure.

Exempts from labeling requirements drug intended to reverse opioid overdose when drug is dispensed by [*physician or physician assistant*] **health care provider**.

A BILL FOR AN ACT

1
2 Relating to opioids.

3 **Be It Enacted by the People of the State of Oregon:**

4 **SECTION 1. Section 2 of this 2023 Act is added to and made a part of ORS chapter 689.**

5 **SECTION 2. (1) A requirement that a health care provider who is authorized to prescribe**
6 **drugs in this state label a drug dispensed by the health care provider with the information**
7 **described in subsection (2) of this section does not apply to a drug approved by the United**
8 **States Food and Drug Administration for the reversal of an opioid overdose if the drug is:**

9 (a) **In the form of a nasal spray; and**

10 (b) **Personally dispensed by a health care provider described in this subsection at the lo-**
11 **cation of practice of the health care provider.**

12 (2) **The information described in subsection (1) of this section includes:**

13 (a) **The name of the patient;**

14 (b) **The name and address of the dispensing health care provider;**

15 (c) **The date of dispensing;**

16 (d)(A) **The name of the drug or, if the dispensed drug does not have a brand name, the**
17 **generic name of the drug along with the name of the drug distributor or manufacturer;**

18 (B) **The drug's quantity per unit, unless the drug is a compound; and**

19 (C) **The directions for the drug's use stated in the prescription;**

20 (e) **Cautionary statements, if any, as required by law; and**

21 (f) **When applicable and as determined by the State Board of Pharmacy, an expiration**
22 **date after which the patient should not use the drug.**

23 **SECTION 3. Section 2 of this 2023 Act applies to dispensations made on or after the ef-**
24 **fective date of this 2023 Act.**

25

NOTE: Matter in **boldfaced** type in an amended section is new; matter [*italic and bracketed*] is existing law to be omitted. New sections are in **boldfaced** type.